CU20200053A7 - Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación - Google Patents

Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación

Info

Publication number
CU20200053A7
CU20200053A7 CU2020000053A CU20200053A CU20200053A7 CU 20200053 A7 CU20200053 A7 CU 20200053A7 CU 2020000053 A CU2020000053 A CU 2020000053A CU 20200053 A CU20200053 A CU 20200053A CU 20200053 A7 CU20200053 A7 CU 20200053A7
Authority
CU
Cuba
Prior art keywords
inhibitor
crystalline form
janocinases
composition
preparation process
Prior art date
Application number
CU2020000053A
Other languages
English (en)
Other versions
CU24671B1 (es
Inventor
Gary E L Brandt
Marta Dabros
Ryan Hudson
Jennifer Kozak
Robert Murray Mckinnell
Jerry Nzerem
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CU20200053A7 publication Critical patent/CU20200053A7/es
Publication of CU24671B1 publication Critical patent/CU24671B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)

Abstract

<p>La invención proporciona un compuesto de Ia fórmula (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>o una sal farmacéuticamente aceptable de este, que es un inhibidor de las janocinasas (JAK), composiciones farmaceúticas que comprenden dicho compuesto y una forma cristalina, útiles para tratar enfermedades inflamatorias de Ia piel y otras enfermedades. La invención también proporciona procesos y productos intermedios útiles para preparar dicho compuesto.</p>
CU2020000053A 2017-10-27 2018-10-26 Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación CU24671B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
CU20200053A7 true CU20200053A7 (es) 2021-03-11
CU24671B1 CU24671B1 (es) 2023-07-12

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000053A CU24671B1 (es) 2017-10-27 2018-10-26 Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación

Country Status (38)

Country Link
US (7) US10308646B2 (es)
EP (1) EP3672965B1 (es)
JP (1) JP7218364B2 (es)
KR (1) KR102613503B1 (es)
CN (1) CN111247142B (es)
AR (1) AR113803A1 (es)
AU (1) AU2018354370B2 (es)
BR (1) BR112020008015A2 (es)
CA (1) CA3074034A1 (es)
CL (1) CL2020001090A1 (es)
CR (1) CR20200180A (es)
CU (1) CU24671B1 (es)
DK (1) DK3672965T3 (es)
DO (1) DOP2020000083A (es)
EA (1) EA202091016A1 (es)
EC (1) ECSP20023795A (es)
ES (1) ES2932526T3 (es)
GE (2) GEP20227344B (es)
HR (1) HRP20221221T1 (es)
HU (1) HUE060401T2 (es)
IL (1) IL274037B2 (es)
LT (1) LT3672965T (es)
MA (1) MA49956B1 (es)
MD (1) MD3672965T2 (es)
MX (1) MX2020004255A (es)
NI (1) NI202000032A (es)
PE (1) PE20201495A1 (es)
PH (1) PH12020500528A1 (es)
PL (1) PL3672965T3 (es)
PT (1) PT3672965T (es)
RS (1) RS63608B1 (es)
SG (1) SG11202001706RA (es)
SI (1) SI3672965T1 (es)
SM (1) SMT202200409T1 (es)
TW (1) TWI789446B (es)
UA (1) UA125130C2 (es)
WO (1) WO2019084383A1 (es)
ZA (1) ZA202001641B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3672965T (pt) 2017-10-27 2022-09-29 Theravance Biopharma R&D Ip Llc Composto de pirimidina como inibidor de jak cinase
CN111511738B (zh) * 2018-11-30 2023-01-20 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
ES2974577T3 (es) 2019-04-24 2024-06-27 Theravance Biopharma R&D Ip Llc Compuestos éster y carbonato de pirimidina como inhibidores de JAK quinasa
AR118767A1 (es) * 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
EP4188333A1 (en) * 2020-07-28 2023-06-07 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
EP4204411A1 (en) * 2020-08-26 2023-07-05 Nalo Therapeutics Modulators of myc family proto-oncogene protein
US20230374124A1 (en) * 2020-10-08 2023-11-23 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
EP4447930A1 (en) 2021-12-15 2024-10-23 Arcutis Biotherapeutics, Inc. Stable formulations of shr0302
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
CA2588220A1 (en) 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
EP1951716B1 (en) 2005-11-16 2011-05-04 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as kinase inhibitors
KR20090024270A (ko) 2006-06-30 2009-03-06 아스트라제네카 아베 암 치료에 유용한 피리미딘 유도체
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
KR20140103972A (ko) 2011-12-22 2014-08-27 에프. 호프만-라 로슈 아게 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
WO2016052930A1 (ko) * 2014-09-30 2016-04-07 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
JP6692836B2 (ja) * 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2017189822A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
PT3672965T (pt) * 2017-10-27 2022-09-29 Theravance Biopharma R&D Ip Llc Composto de pirimidina como inibidor de jak cinase
AR118767A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
ES2974577T3 (es) 2019-04-24 2024-06-27 Theravance Biopharma R&D Ip Llc Compuestos éster y carbonato de pirimidina como inhibidores de JAK quinasa

Also Published As

Publication number Publication date
JP2021501151A (ja) 2021-01-14
DK3672965T3 (da) 2022-10-03
LT3672965T (lt) 2022-10-10
CA3074034A1 (en) 2019-05-02
ES2932526T3 (es) 2023-01-20
PL3672965T3 (pl) 2023-01-16
HRP20221221T1 (hr) 2022-12-09
CN111247142A (zh) 2020-06-05
MA49956A (fr) 2020-07-01
TWI789446B (zh) 2023-01-11
CU24671B1 (es) 2023-07-12
US20220396573A1 (en) 2022-12-15
US11420965B2 (en) 2022-08-23
CL2020001090A1 (es) 2020-08-21
US11814377B2 (en) 2023-11-14
US20200369660A1 (en) 2020-11-26
US20210214349A1 (en) 2021-07-15
US20200140430A1 (en) 2020-05-07
KR102613503B1 (ko) 2023-12-13
US12172994B2 (en) 2024-12-24
JP7218364B2 (ja) 2023-02-06
EA202091016A1 (ru) 2020-07-17
AR113803A1 (es) 2020-06-10
TW201930304A (zh) 2019-08-01
US10988470B2 (en) 2021-04-27
NI202000032A (es) 2020-10-09
US10774080B2 (en) 2020-09-15
IL274037A (en) 2020-06-30
CN111247142B (zh) 2022-12-02
US20190127364A1 (en) 2019-05-02
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
BR112020008015A2 (pt) 2020-10-27
AU2018354370B2 (en) 2023-04-27
GEP20227344B (en) 2022-01-25
SI3672965T1 (sl) 2022-11-30
HUE060401T2 (hu) 2023-02-28
US20240158389A1 (en) 2024-05-16
SG11202001706RA (en) 2020-03-30
DOP2020000083A (es) 2020-08-15
EP3672965A1 (en) 2020-07-01
US10562894B2 (en) 2020-02-18
WO2019084383A1 (en) 2019-05-02
PT3672965T (pt) 2022-09-29
ZA202001641B (en) 2021-04-28
RS63608B1 (sr) 2022-10-31
CR20200180A (es) 2020-08-12
US20190241555A1 (en) 2019-08-08
PH12020500528A1 (en) 2021-06-07
AU2018354370A1 (en) 2020-04-09
MD3672965T2 (ro) 2022-12-31
ECSP20023795A (es) 2020-06-30
EP3672965B1 (en) 2022-09-07
UA125130C2 (uk) 2022-01-12
IL274037B1 (en) 2023-07-01
IL274037B2 (en) 2023-11-01
KR20200078517A (ko) 2020-07-01
PE20201495A1 (es) 2020-12-29
GEAP202115340A (en) 2021-08-10
MX2020004255A (es) 2020-07-29
MA49956B1 (fr) 2022-11-30

Similar Documents

Publication Publication Date Title
CU20200053A7 (es) Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2020001469A2 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201791576A1 (ru) Ингибитор jak
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
MX2019014054A (es) Profarmacos de glucuronida de inhibidores de la cinasa janus.
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana